In 2011, the first-generation ALK-TKI, crizotinib was approved for treatment of advanced ALK-positive NSCLC, which is a small molecule ATP-competitive ALK inhibitor [17]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.